BioSpace

AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals

Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.

By BioSpace

1 min read
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights